List view / Grid view
The European Investment Bank (EIB) will provide three €25 million instalments to support CureVac’s vaccine development and expansion to mRNA production facilities.
Extensive analysis of interim data finds patients given cabotegravir injection had a 66 percent lower incidence of HIV acquisition than those taking Truvada pills.
The Drug Controller General of India (DCGI) approved remdesivir lyophilised powder for emergency use in patients hospitalised with severe COVID-19.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
New data models need to be built rapidly to respond to the COVID-19 pandemic. Matt Jones explains how to do it.
Companies leading trial announce Kevzara failed to meet primary and secondary endpoints in critically ill COVID-19 patients, so the trial has been halted.
The European Investment Bank (EIB), in partnership with the European Commission (EC), have pledged an additional €4.9 billion for use in the global coronavirus response funds.
CanSino Biologics' Ad5-nCoV vaccine, a potential COVID-19 prophylactic, has been approved for study in a Phase I clinical trial in China.
Gilead has announced that the potential COVID-19 drug remdesivir will cost $390 per vial for developed countries, with treatment courses costing $2,340 per patient.
Indian authorities have given the green light to test Bharat Biotech's COVID-19 vaccine in Phase I and Phase II clinical trials.
A study has found that chemotherapy and surgery do not correlate with worse COVID-19 outcomes for cancer patients, whereas taking immune checkpoint inhibitors does.
Dr Madhav Durbha explains the importance of implementing and ensuring stable supply chains to deliver potential COVID-19 vaccines.
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
The promise of virally vectored DNA and mRNA vaccines is tremendous in terms of vaccine safety and speed of response to new pathogens. This article explores why these approaches have attracted attention in light of the COVID-19 pandemic and why they are highly appropriate for rapid vaccine development and deployment.
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
